| Identification | Back Directory | [Name]
14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) | [CAS]
1228923-42-9 | [Synonyms]
Pacetinib citrate
Pacritinib Citrate
14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) | [Molecular Formula]
C34H40N4O10 | [MOL File]
1228923-42-9.mol | [Molecular Weight]
664.71 |
| Hazard Information | Back Directory | [Uses]
Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib citrate also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3]. | [References]
[1] Hart S, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011 Nov;25(11):1751-9. DOI:10.1038/leu.2011.148
[2] Hart S, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011 Nov;1(11):e44. DOI:10.1038/bcj.2011.43
[3] Komrokji RS, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23;125(17):2649-55. DOI:10.1182/blood-2013-02-484832 |
|
|